Skip to content
Inciteful Med
Resources About us Ask a Question

Can Solitary Fibrous Tumor (SFT) Come Back Years Later?

Published: | Updated:

Yes, a solitary fibrous tumor (SFT) can return years or decades after successful removal. Because of this late recurrence risk, doctors use the term 'No Evidence of Disease' (NED) instead of 'cured.' Patients require lifelong surveillance scans to detect any returning tumors early.

Key Takeaways

  • • Solitary fibrous tumors have a unique potential to return decades after the initial surgery.
  • • Doctors use the term 'No Evidence of Disease' (NED) instead of 'cured' to emphasize the need for ongoing vigilance.
  • • Routine, lifelong imaging scans are required because recurrent tumors often grow without causing any noticeable symptoms.
  • • Pathologists estimate recurrence risk using the Demicco score and genetic markers like the TERT promoter mutation.

Yes, a solitary fibrous tumor (SFT) can come back years or even decades after a successful surgery [1][2]. Unlike many other types of tumors or cancers where a patient is considered “in the clear” after five years, SFTs are known for their unpredictable behavior and potential for very late recurrence [3][4]. Cases of SFT returning 10, 20, or even 40 years after the initial tumor was removed have been documented in medical literature [5][6]. Because of this unique biology, doctors use specific terminology to describe your status after treatment.

Why Doctors Say “NED” Instead of “Cured”

Hearing that you are not “cured” after a successful surgery can be incredibly frustrating and emotionally difficult. However, your doctor’s use of the term NED (No Evidence of Disease) is a precise reflection of how SFT behaves [7].

  • Cured implies that the disease is permanently gone and there is virtually no risk of it ever returning. Because SFTs have a documented history of recurring long after surgery, doctors cannot guarantee that every microscopic cell was eliminated [8][2].
  • No Evidence of Disease (NED) means exactly what it says: based on your current physical exams and imaging scans (like CTs or MRIs), the doctor cannot find any trace of the tumor [7][9].

Using “NED” instead of “cured” is not meant to take away your hope. Rather, it is a clinical safeguard [7][1]. It ensures that both you and your medical team remain vigilant and understand the absolute necessity of lifelong monitoring.

The Reality of Late Recurrence

SFTs can recur in two main ways: local recurrence (growing back in the exact same spot where the original tumor was removed) or distant metastasis (spreading to other parts of the body, such as the lungs, liver, or bones) [10][11].

Even tumors that were originally classified as “low-risk” or “benign” under a microscope still carry a risk of coming back years later [4][12]. The tumor cells can lie dormant in the body for long periods before they start to grow again, which is why a “clear” scan at year 5 or year 10 does not mean you can stop getting scans [13][14].

Often, late recurrences are completely asymptomatic, meaning you won’t feel sick while the tumor is growing [15][16]. This is exactly why routine scans are required—waiting until you have symptoms defeats the purpose of early detection [17]. However, between scheduled scans, you should always notify your doctor if you experience new, persistent symptoms such as an unexplained lump at your surgery site, lingering cough, or unusual pain [16][11].

Understanding Your Personal Risk

While all SFTs require long-term follow-up, your individual risk of the tumor returning depends on several factors [12][18]. Pathologists use scoring systems, such as the Demicco risk stratification model, to estimate how likely the tumor is to spread [19]. This model looks at:

  • Patient age at diagnosis [20]
  • Tumor size (larger tumors generally have a higher risk) [19]
  • Mitotic rate (how many cells are actively dividing under a microscope) [19][21]
  • Necrosis (whether there is dead tissue within the tumor, which indicates aggressive growth) [19]

Additionally, doctors are increasingly looking at specific genetic markers. For example, a mutation in the TERT promoter gene is strongly linked to more aggressive behavior and a higher risk of the tumor returning [22][23]. Depending on these factors, your doctor will classify your SFT as low, intermediate, or high risk, which helps dictate how frequently you need scans [24][25].

Note for patients: The Demicco score and TERT testing might not automatically be highlighted or even run on older pathology reports. It is highly recommended to ask your oncologist or a sarcoma specialist if these tests have been completed to help tailor your follow-up care.

The Importance of Lifelong Surveillance

Because there is no universal timeline where an SFT patient is declared permanently disease-free, clinical consensus mandates long-term, potentially indefinite follow-up [2][26]. Given the rarity of SFTs, it is best to have this long-term surveillance coordinated by a sarcoma specialist rather than a general practitioner [11][17].

Your surveillance plan will likely involve periodic cross-sectional imaging, such as CT or MRI scans of the primary tumor site and your chest/abdomen [27][28]. The frequency of these scans might decrease over time—for instance, moving from every 6 months to once a year—but they should never stop entirely [13][29].

Staying in “NED” status is a victory worth celebrating. Continuing your lifelong scan schedule is simply the tool you use to protect that victory, ensuring that if a recurrence does happen, it is caught as early as possible when it is most treatable [17][11].

Frequently Asked Questions

Why do doctors say I am 'NED' instead of cured from SFT?
Doctors use 'No Evidence of Disease' (NED) instead of 'cured' because solitary fibrous tumors have a known history of returning long after surgery. NED means that current scans and exams show no trace of the tumor, but lifelong monitoring is still required.
Can a solitary fibrous tumor come back decades later?
Yes, it is possible for a solitary fibrous tumor to return 10, 20, or even 40 years after the original tumor was successfully removed. Because these tumor cells can lie dormant for long periods, lifelong follow-up scans are essential.
What factors increase the risk of my SFT returning?
Doctors use the Demicco scoring system to estimate your risk of recurrence. This looks at your age, the tumor's size, how actively the cells are dividing, and if there is dead tissue. Specific genetic markers like the TERT promoter mutation also indicate a higher risk.
What are the warning signs that my SFT has returned?
Many late recurrences have no symptoms and are only found during routine scans, which is why keeping up with imaging is critical. However, warning signs can include an unexplained lump at your original surgery site, a lingering cough, or unusual pain that does not go away.

Questions for Your Doctor

  • • What was my Demicco risk score based on my pathology report, and how does it affect my scan schedule?
  • • Was my tumor tissue tested for the TERT promoter mutation, and if not, can we request that testing?
  • • What specific imaging modalities (CT, MRI) will we use for my long-term surveillance, and how often will I need them over the next decade?
  • • Who should be the primary doctor managing my lifelong surveillance—you, a medical oncologist, or a sarcoma specialist?
  • • What specific physical symptoms or warning signs should prompt me to call your office between my scheduled scans?

Questions for You

  • • Have I obtained and kept a copy of my complete post-surgery pathology report for my own records?
  • • How am I managing the emotional stress or 'scanxiety' that comes with long-term surveillance?
  • • Am I currently experiencing any new, unexplained physical symptoms near my original surgery site or elsewhere?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature.

    Lavacchi D, Antonuzzo L, Briganti V, et al.

    Anti-cancer drugs 2020; (31(6)):646-651 doi:10.1097/CAD.0000000000000900.

    PMID: 31972591
  2. 2

    Pathological Features and Clinical Course in Patients With Recurrent or Malignant Orbital Solitary Fibrous Tumor/Hemangiopericytoma.

    Sagiv O, Bell D, Guo Y, et al.

    Ophthalmic plastic and reconstructive surgery 2019; (35(2)):148-154 doi:10.1097/IOP.0000000000001189.

    PMID: 30371551
  3. 3

    A Rare Case of Solitary Fibrous Tumor Originating in the Peritoneum: Clinical and Histopathological Insights.

    Balaji AN, Balasubramanian B, Tarawneh BA

    Cureus 2024; (16(10)):e72082 doi:10.7759/cureus.72082.

    PMID: 39574987
  4. 4

    Hemangiopericytoma/Solitary Fibrous Tumor in the central nervous system. Experience with surgery and radiotherapy as a complementary treatment: A 10-year analysis of a heterogeneous series in a single tertiary center.

    González-Vargas PM, Thenier-Villa JL, Sanromán Álvarez P, et al.

    Neurocirugia 2020; (31(1)):14-23 doi:10.1016/j.neucir.2019.06.001.

    PMID: 31351895
  5. 5

    A case of primary orbital solitary fibrous tumor with lung metastases 41 years after initial treatment.

    Tanabe M, Yoshikawa H, Yamada Y, et al.

    Orbit (Amsterdam, Netherlands) 2022; (41(6)):810-814 doi:10.1080/01676830.2021.1954665.

    PMID: 34261401
  6. 6

    Solitary Fibrous Tumors of the Head and Neck: A Single-Institution Study of 52 Patients.

    Chung HR, Tam K, Han AY, et al.

    OTO open 2022; (6(3)):2473974X221098709 doi:10.1177/2473974X221098709.

    PMID: 35845143
  7. 7

    Grade III solitary fibrous tumor/hemangiopericytoma: An enthralling intracranial tumor-A case report and literature review.

    Al Armashi AR, Alkrekshi A, Al Zubaidi A, et al.

    Radiology case reports 2022; (17(10)):3792-3796 doi:10.1016/j.radcr.2022.07.007.

    PMID: 35965927
  8. 8

    A dedifferentiated intracranial solitary fibrous tumor with osteosarcoma components: rapid tumor progression and lethal clinical course.

    Kambe A, Nakada S, Nagao Y, et al.

    Brain tumor pathology 2020; (37(4)):165-170 doi:10.1007/s10014-020-00374-y.

    PMID: 32740753
  9. 9

    [Solitary fibrous tumor/hemangiopericytoma].

    Teranishi Y, Hongou H, Miyawaki S, Saito N

    No shinkei geka. Neurological surgery 2022; (50(1)):141-149 doi:10.11477/mf.1436204539.

    PMID: 35169094
  10. 10

    Solitary fibrous tumor of the kidney: A case report.

    Zaghbib S, Chakroun M, Essid MA, et al.

    International journal of surgery case reports 2019; (62()):112-114 doi:10.1016/j.ijscr.2019.08.004.

    PMID: 31494455
  11. 11

    A Rare Case of Metastatic Solitary Fibrous Tumor (Hemangiopericytoma) of the Dura on 18F-FDG PET/CT.

    Grünig H, Skawran S, Stolzmann P, et al.

    Clinical nuclear medicine 2021; (46(9)):768-769 doi:10.1097/RLU.0000000000003626.

    PMID: 34288634
  12. 12

    Resection of an intrapulmonary solitary fibrous tumor in the center of the middle lobe: a case report.

    Hirai Y, Iwahashi Y, Kogure M, et al.

    Journal of surgical case reports 2022; (2022(10)):rjac466 doi:10.1093/jscr/rjac466.

    PMID: 36245559
  13. 13

    Evaluation of Alternative Risk Stratification Systems in a Large Series of Solitary Fibrous Tumors with Molecular Findings and Ki-67 Index Data: Do They Improve Risk Assessment?

    Machado I, Blázquez Bujeda Á, Giner F, et al.

    International journal of molecular sciences 2022; (24(1)) doi:10.3390/ijms24010439.

    PMID: 36613891
  14. 14

    A broad ligament solitary fibrous tumor with Doege-Potter syndrome.

    Chen S, Zheng Y, Chen L, Yi Q

    Medicine 2018; (97(39)):e12564 doi:10.1097/MD.0000000000012564.

    PMID: 30278559
  15. 15

    Doege-Potter syndrome associated to metastatic solitary fibrous tumor.

    Andrade MO, de Sousa NDC, do Amaral PS, et al.

    Autopsy & case reports 2022; (12()):e2021412 doi:10.4322/acr.2021.412.

    PMID: 36569984
  16. 16

    Non-Islet Cell Tumor Hypoglycemia Caused by Recurrent Pelvic Solitary Fibrous Tumor.

    Pinho Dos Santos D, Correia R, Carragoso A, et al.

    Cureus 2021; (13(1)):e12878 doi:10.7759/cureus.12878.

    PMID: 33633907
  17. 17

    Long-Term Surgical Outcome for Orbital Solitary Fibrous Tumors.

    Vahdani K, Rose GE, Verity DH

    Ophthalmic plastic and reconstructive surgery 2023; (39(6)):606-613 doi:10.1097/IOP.0000000000002446.

    PMID: 37405750
  18. 18

    A review of solitary fibrous tumor/hemangiopericytoma tumor and a comparison of risk factors for recurrence, metastases, and death among patients with spinal and intracranial tumors.

    Giordan E, Marton E, Wennberg AM, et al.

    Neurosurgical review 2021; (44(3)):1299-1312 doi:10.1007/s10143-020-01335-x.

    PMID: 32556679
  19. 19

    Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model.

    Demicco EG, Wagner MJ, Maki RG, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017; (30(10)):1433-1442 doi:10.1038/modpathol.2017.54.

    PMID: 28731041
  20. 20

    Solitary Fibrous Tumour: A Single Institution Retrospective Study and Further Validation of a Prognostic Risk Assessment System.

    Friis RB, Safwat A, Baad-Hansen T, Aggerholm-Pedersen N

    Clinical oncology (Royal College of Radiologists (Great Britain)) 2018; (30(12)):798-804 doi:10.1016/j.clon.2018.08.015.

    PMID: 30206022
  21. 21

    A Rare Case of Solitary Fibrous Tumor Involving the Nasolacrimal Duct System in a 12-Year-Old Female: A Case Report and Review of the Literature.

    Sheth NT, Adetunji MO, Smith ET, et al.

    Ophthalmic plastic and reconstructive surgery 2025; (41(3)):e89-e95 doi:10.1097/IOP.0000000000002854.

    PMID: 39700394
  22. 22

    TERT promoter mutations and prognosis in solitary fibrous tumor.

    Bahrami A, Lee S, Schaefer IM, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016; (29(12)):1511-1522 doi:10.1038/modpathol.2016.126.

    PMID: 27562490
  23. 23

    Effect of Different Treatments for Intracranial Solitary Fibrous Tumors: Retrospective Analysis of 31 Patients.

    Li Q, Deng W, Sun P

    World neurosurgery 2022; (166()):e60-e69 doi:10.1016/j.wneu.2022.06.089.

    PMID: 35760325
  24. 24

    Prognostic usefulness of a modified risk model for solitary fibrous tumor that includes the Ki-67 labeling index.

    Sugita S, Segawa K, Kikuchi N, et al.

    World journal of surgical oncology 2022; (20(1)):29 doi:10.1186/s12957-022-02497-2.

    PMID: 35105348
  25. 25

    Solitary fibrous tumor of thoracic cavity, extra-thoracic sites and central nervous system: Clinicopathologic features and association with local recurrence and metastasis.

    Alexiev BA, Finkelman BS, Streich L, et al.

    Pathology, research and practice 2021; (224()):153531 doi:10.1016/j.prp.2021.153531.

    PMID: 34171600
  26. 26

    A rare mesenchymal neoplasm at unusual location: Solitary fibrous tumor of vulva.

    Nag G, Rao SR

    Gynecologic oncology reports 2015; (12()):52-4 doi:10.1016/j.gore.2015.03.002.

    PMID: 26076159
  27. 27

    Solitary Fibrous Tumor of the Prostate Shown on FAPI PET/CT.

    Yang T, Zhu R, Guo Z, et al.

    Clinical nuclear medicine 2023; (48(6)):530-531 doi:10.1097/RLU.0000000000004635.

    PMID: 37133513
  28. 28

    Teaching NeuroImage: Intracranial Solitary Fibrous Tumor With Liver Metastasis.

    Webb MJ, Campian JL, Sener U

    Neurology 2023; (100(18)):884-885 doi:10.1212/WNL.0000000000206822.

    PMID: 36564211
  29. 29

    Solitary fibrous tumor of the pineal region with delayed ectopic intracranial metastasis: A case report and review of the literature.

    Wang Y, Zhang J, Liu Q, et al.

    Medicine 2019; (98(21)):e15737 doi:10.1097/MD.0000000000015737.

    PMID: 31124953

This page provides general information about SFT recurrence and long-term surveillance. Always discuss your individual recurrence risk and follow-up scan schedule with your oncologist or sarcoma specialist.

Stay up to date

Get notified when new research about Solitary Fibrous Tumor (SFT) is published.

No spam. Unsubscribe anytime.